Synopsis
Synopsis
0
USDMF
0
CEP/COS
0
JDMF
0
EU WC
0
VMF
0
FDA Orange Book
0
Canada
0
Australia
0
South Africa
DRUG PRODUCT COMPOSITIONS
0
EDQM
0
USP
0
JP
0
Others
0
US Patents
0
US Exclusivities
0
Health Canada Patents
0
Data Compilation #PharmaFlow
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
0
News #PharmaBuzz
1. 3-((5-oxo-2-pyrrolidinyl)carbonyl)-4-thiazolidinecarboxylic Acid
2. 3-pyroglutamylthiazolidine-4-carboxylic Acid
3. 3-pyroglutamylthiazolidine-4-carboxylic Acid, (r-(r*,s*))-isomer
4. Adimod
5. Pgt-1a
1. 121808-62-6
2. (r)-3-((s)-5-oxopyrrolidine-2-carbonyl)thiazolidine-4-carboxylic Acid
3. Pidotomod
4. Pidotimod [inn]
5. Pgt/1a
6. Pilimod
7. Nsc-759841
8. (r)-3-((s)-5-oxoprolyl)-4-thiazolidinecarboxylic Acid
9. Pidotimod (inn)
10. (4r)-3-[(2s)-5-oxopyrrolidine-2-carbonyl]-1,3-thiazolidine-4-carboxylic Acid
11. Ncgc00160516-01
12. Polimod
13. (4r)-3-{[(2s)-5-oxopyrrolidin-2-yl]carbonyl}-1,3-thiazolidine-4-carboxylic Acid
14. 785363r681
15. Pidotimodum
16. Pigitil
17. Pidotimodum [inn-latin]
18. 4-thiazolidinecarboxylic Acid, 3-[[(2s)-5-oxo-2-pyrrolidinyl]carbonyl]-, (4r)-
19. Smr000466390
20. Ccris 7271
21. Brn 6636310
22. Onaka
23. Thymodolic Acid
24. Axil
25. Timodolic Acid
26. Pilimod (tn)
27. Pidotimod - Bio-x
28. Unii-785363r681
29. Pidotimod [mi]
30. Pidotimod [mart.]
31. (r-(r*,s*))-3-((5-oxo-2-pyrrolidinyl)carbonyl)-4-thiazolidinecarboxylic Acid
32. Pidotimod [who-dd]
33. (4r)-3-[[(2s)-5-oxo-2-pyrrolidinyl]carbonyl]-4-thiazolidinecarboxylic Acid
34. (r)-3-((s)-(5-oxo-2-pyrrolidinyl)carbonyl)-thiazolidin-4-carbonsaeure [german]
35. Dsstox_cid_26199
36. Dsstox_rid_81430
37. Dsstox_gsid_46199
38. Mls000759528
39. Mls001032108
40. Mls001216453
41. Mls001423953
42. Schembl138407
43. Chembl1488165
44. Dtxsid0046199
45. Pidotimod, >=98% (hplc)
46. Chebi:94618
47. Hms2051c04
48. Hms2231m03
49. Hms3715h06
50. Pharmakon1600-01502322
51. Bcp05222
52. Hy-b0944
53. Zinc3781245
54. Tox21_111865
55. Mfcd00867583
56. Nsc759841
57. S3106
58. (r)-3-((s)-(5-oxo-2-pyrrolidinyl)carbonyl)-thiazolidin-4-carbonsaeure
59. Akos015896354
60. Ac-3493
61. Am90280
62. Ccg-100832
63. Db11364
64. Ks-5229
65. Nc00082
66. Nsc 759841
67. (r)-3-[[(s)-5-oxo-2-pyrrolidinyl]carbonyl]-1,3-thiazolidine-4-carboxylic Acid
68. 4-thiazolidinecarboxylic Acid, 3-((5-oxo-2-pyrrolidinyl)carbonyl)-, (r-(r*,s*))-
69. Ncgc00160516-03
70. Bp164260
71. Cas-121808-62-6
72. P2147
73. Sw197462-2
74. D07261
75. Ab00639966-08
76. Ab00639966_10
77. Ab00639966_11
78. 808p626
79. A804790
80. J-502193
81. Q3902720
82. (4r)-3-[(2s)-5-oxopyrrolidine-2-carbonyl]thiazolidine-4-carboxylic Acid;pidotimod
83. (4r)-3-[[(2s)-5-oxo-2-pyrrolidinyl]carbonyl]thiazolidine-4-carboxylic Acid
84. (4r)-3-[oxo-[(2s)-5-oxo-2-pyrrolidinyl]methyl]-4-thiazolidinecarboxylic Acid
Molecular Weight | 244.27 g/mol |
---|---|
Molecular Formula | C9H12N2O4S |
XLogP3 | -0.7 |
Hydrogen Bond Donor Count | 2 |
Hydrogen Bond Acceptor Count | 5 |
Rotatable Bond Count | 2 |
Exact Mass | 244.05177804 g/mol |
Monoisotopic Mass | 244.05177804 g/mol |
Topological Polar Surface Area | 112 Ų |
Heavy Atom Count | 16 |
Formal Charge | 0 |
Complexity | 346 |
Isotope Atom Count | 0 |
Defined Atom Stereocenter Count | 2 |
Undefined Atom Stereocenter Count | 0 |
Defined Bond Stereocenter Count | 0 |
Undefined Bond Stereocenter Count | 0 |
Covalently Bonded Unit Count | 1 |
For use as immunostimulant therapy for treatment of cell-mediated immunosuppression with respiratory or urinary infections.
Pidotimod modulates the immune system to induce an immune response against bacterial or viral pathogens
Adjuvants, Immunologic
Substances that augment, stimulate, activate, potentiate, or modulate the immune response at either the cellular or humoral level. The classical agents (Freund's adjuvant, BCG, Corynebacterium parvum, et al.) contain bacterial antigens. Some are endogenous (e.g., histamine, interferon, transfer factor, tuftsin, interleukin-1). Their mode of action is either non-specific, resulting in increased immune responsiveness to a wide variety of antigens, or antigen-specific, i.e., affecting a restricted type of immune response to a narrow group of antigens. The therapeutic efficacy of many biological response modifiers is related to their antigen-specific immunoadjuvanticity. (See all compounds classified as Adjuvants, Immunologic.)
Immunologic Factors
Biologically active substances whose activities affect or play a role in the functioning of the immune system. (See all compounds classified as Immunologic Factors.)
L - Antineoplastic and immunomodulating agents
L03 - Immunostimulants
L03A - Immunostimulants
L03AX - Other immunostimulants
L03AX05 - Pidotimod
Absorption
Bioavailability of 45%.
Route of Elimination
95% of intravenous dose is eliminated in the urine as the parent compound.
Half life of 4 h.
Pidotimod inhibits tumor necrosis factor (TNF-) induced increases in extracellular signal-related kinase (ERK) phosphorylation. It also increases nuclear factor B (NFB) expression and translocation to the nucleus. It is these to modulatory effects on ERK and NFB signalling which are thought to produce the increase in toll-like receptor expression seen with pidotimod. Pidotimod increase maturation of dendritic cells responsible for presenting antigens to naive Th-cells. It also appears to result in a greater population these cells diiferentiating to Th1 cells which are believed to mediate the immune response to pathogens like bacteria and viruses. Lastly, pidotimod appears to increase antigen-specific antibody titer and cytotoxic response with antigen exposure. The precise mechanism and timeline of events leading to these effects is unknown.
Chynops Pharma is an ideal sourcing partner for high-quality APIs, advanced intermediates, speciality chemicals & excipients.
Jinan Tantu Chemicals offers customized R&D services & production of small molecule APIs & pharmaceutical intermediates.
Registrant Name : Samoh Pharmaceutical Co., Ltd.
Registration Date : 2021-12-15
Registration Number : 20211215-211-J-1179
Manufacturer Name : Wockhardt Limited
Manufacturer Address : Plot No. 138, Ankleshwar-393 002, Dist. Bharuch, Gujarat State, India
Registrant Name : Masung LS Co., Ltd.
Registration Date : 2022-05-24
Registration Number : 20220524-211-J-1303
Manufacturer Name : Beijing Jincheng Taier Pharm...
Manufacturer Address : The eastern longitute 5 Road, Northern latitude 2 Road of Beijing Pharmaceutical Indu...
Registrant Name : Samoh Pharmaceutical Co., Ltd.
Registration Date : 2021-12-15
Registration Number : 20211215-211-J-1179
Manufacturer Name : Wockhardt Limited
Manufacturer Address : Plot No. 138, Ankleshwar-393 002, Dist. Bharuch, Gujarat State, India
API Imports and Exports
Importing Country | Total Quantity (KGS) |
Average Price (USD/KGS) |
Number of Transactions |
---|
Upgrade, download data, analyse, strategize, subscribe with us
Regulatory Info :
Registration Country : Italy
Brand Name : ONAKA
Dosage Form : Sachet
Dosage Strength : 800MG
Packaging : 10 sachets
Approval Date :
Application Number :
Regulatory Info :
Registration Country : Italy
Packaging : 10 sachets
Regulatory Info :
Dosage : Sachet
Dosage Strength : 800MG
Brand Name : ONAKA
Approval Date :
Application Number :
Registration Country : Italy
Regulatory Info :
Registration Country : Italy
Brand Name : ONAKA
Dosage Form : Vials
Dosage Strength : 400MG
Packaging : 10 vials
Approval Date :
Application Number :
Regulatory Info :
Registration Country : Italy
Packaging : 10 vials
Regulatory Info :
Dosage : Vials
Dosage Strength : 400MG
Brand Name : ONAKA
Approval Date :
Application Number :
Registration Country : Italy
Global Sales Information
DOROM Srl
Dosage Form :
Dosage Strength : 10 Bust Grat 800 Mg
Price Per Pack (Euro) : 26.9
Published in :
Country : Italy
RX/OTC/DISCN : Class C
Portfolio PDF
Product Web Link
Virtual Booth
Digital Content
Website
Corporate PDF
DOROM Srl
Dosage Form :
Dosage Strength : Os Soluz 10 Vials 400 Mg
Price Per Pack (Euro) : 22.9
Published in :
Country : Italy
RX/OTC/DISCN : Class C
Portfolio PDF
Product Web Link
Virtual Booth
Digital Content
Website
Corporate PDF
MARVECSPHARMA SERVICES Srl
Dosage Form :
Dosage Strength : 10 Bust Groun Os 800 Mg
Price Per Pack (Euro) : 27.44
Published in :
Country : Italy
RX/OTC/DISCN : Class C
Portfolio PDF
Product Web Link
Virtual Booth
Digital Content
Website
Corporate PDF
MARVECSPHARMA SERVICES Srl
Dosage Form :
Dosage Strength : Os Soluz 10 Vials 400 Mg
Price Per Pack (Euro) : 23.36
Published in :
Country : Italy
RX/OTC/DISCN : Class C
Portfolio PDF
Product Web Link
Virtual Booth
Digital Content
Website
Corporate PDF
MAX FARMA Srl
Dosage Form :
Dosage Strength : 10 Bust Grat 800 Mg
Price Per Pack (Euro) : 26.9
Published in :
Country : Italy
RX/OTC/DISCN : Class C
Portfolio PDF
Product Web Link
Virtual Booth
Digital Content
Website
Corporate PDF
MAX FARMA Srl
Dosage Form :
Dosage Strength : Os Soluz 10 Vials 400 Mg
Price Per Pack (Euro) : 22.9
Published in :
Country : Italy
RX/OTC/DISCN : Class C
Portfolio PDF
Product Web Link
Virtual Booth
Digital Content
Website
Corporate PDF
Market Place
ABOUT THIS PAGE
A Pidotimod manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Pidotimod, including repackagers and relabelers. The FDA regulates Pidotimod manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Pidotimod API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
click here to find a list of Pidotimod manufacturers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PhamaCompass.
A Pidotimod supplier is an individual or a company that provides Pidotimod active pharmaceutical ingredient (API) or Pidotimod finished formulations upon request. The Pidotimod suppliers may include Pidotimod API manufacturers, exporters, distributors and traders.
click here to find a list of Pidotimod suppliers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PharmaCompass.
In Korea, the Ministry of Food and Drug Safety (MFDS) is in charge of regulating pharmaceutical products and services.
Pharmaceutical companies submit a Pidotimod Drug Master File in Korea (Pidotimod KDMF) to the MFDS, which includes comprehensive information about the production, processing, facilities, materials, packaging, and testing of Pidotimod. The MFDS reviews the Pidotimod KDMF as part of the drug registration process and uses the information provided in the Pidotimod KDMF to evaluate the safety and efficacy of the drug.
After submitting a Pidotimod KDMF to the MFDS, the registered manufacturer can provide importers or distributors with the registration number without revealing confidential information to Korean business partners. Applicants seeking to register their Pidotimod API can apply through the Korea Drug Master File (KDMF).
click here to find a list of Pidotimod suppliers with KDMF on PharmaCompass.
National Drug Code is a comprehensive database maintained by the FDA that contains information on all drugs marketed in the US. This directory includes information about finished drug products, unfinished drug products, and compounded drug products, including those containing Pidotimod as an active pharmaceutical ingredient (API).
The FDA updates the NDC directory daily. The NDC numbers for Pidotimod API and other APIs are published in this directory by the FDA.
The NDC unfinished drugs database includes product listing information submitted for all unfinished drugs, such as active pharmaceutical ingredients (APIs), drugs intended for further processing and bulk drug substances for compounding.
Pharmaceutical companies that manufacture Pidotimod as an active pharmaceutical ingredient (API) must furnish the FDA with an updated record of all drugs that they produce, prepare, propagate, compound, or process for commercial distribution in the US at their facilities.
The NDC directory also contains data on finished compounded human drug products that contain Pidotimod and are produced by outsourcing facilities. While these outsourcing facilities are not mandated to assign a Pidotimod NDC to their finished compounded human drug products, they may choose to do so.
click here to find a list of Pidotimod suppliers with NDC on PharmaCompass.
Pidotimod Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of Pidotimod GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right Pidotimod GMP manufacturer or Pidotimod GMP API supplier for your needs.
A Pidotimod CoA (Certificate of Analysis) is a formal document that attests to Pidotimod's compliance with Pidotimod specifications and serves as a tool for batch-level quality control.
Pidotimod CoA mostly includes findings from lab analyses of a specific batch. For each Pidotimod CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
Pidotimod may be tested according to a variety of international standards, such as European Pharmacopoeia (Pidotimod EP), Pidotimod JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Pidotimod USP).
LOOKING FOR A SUPPLIER?